| First Author | Kel JM | Year | 2008 |
| Journal | Int Immunol | Volume | 20 |
| Issue | 1 | Pages | 117-27 |
| PubMed ID | 18024466 | Mgi Jnum | J:130224 |
| Mgi Id | MGI:3771265 | Doi | 10.1093/intimm/dxm123 |
| Citation | Kel JM, et al. (2008) Immunization with mannosylated peptide induces poor T cell effector functions despite enhanced antigen presentation. Int Immunol 20(1):117-27 |
| abstractText | In this study, we investigated the development of T cell responses in mice after administration of a mannosylated ovalbumin peptide (M-OVA(323-339)). Immunization with M-OVA(323-339) in complete adjuvant resulted in enhanced antigen presentation in draining lymph nodes. Monitoring the fate of CFSE-labeled ovalbumin peptide-specific TCR transgenic CD4(+) T cells revealed that immunization with M-OVA(323-339) induced normal clonal expansion, recirculation and CD62L expression of antigen-specific T cells in vivo. However, these T cells developed only poor effector functions, reflected by minimal IFN-gamma production, low IgG2a levels in serum and poor peptide-specific delayed-type hypersensitivity (DTH) responses. This diminished inflammatory response was associated with decreased infiltration of T cell blasts and macrophages. Importantly, also mice with functional effector T cells did not mount a robust DTH response after a challenge with M-OVA(323-339) in the ear, although their T cells responded normally to M-OVA(323-339) in vitro. In conclusion, mannosylated peptide induces proliferation of T cells with impaired T(h)1 cell effector functions and additionally abrogates the activity of pre-existing effector T cells. |
